Trial NCT04262375

View at ClinicalTrials.gov 
Org. Study IDs: DOMINATION
Secondary IDs: 19-6281

Last trial update was posted on 2020-11-17

MeSH Interventions

Durvalumab

MeSH Conditions

Carcinoma, Renal Cell

Other Conditions

Non Small Cell Lung Cancer Renal Cell Carcinoma

Stopping Reasons

Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID